What stage is this research study?
This trial is a Phase 3 study.
This trial is a Phase 3 study.
The purpose of this research study is to evaluate the safety and efficacy of SRP-4045 and SRP-4053 in individuals with Duchenne who have a deletion that is amenable to exon 45 or exon 53 skipping.
This study is sponsored by Sarepta Therapeutics.
As of April 2018, ESSENCE has reached targeted enrollment in the US and is no longer enrolling patients in the US. Enrollment is continuing in other countries. The study is enrolling individuals with Duchenne with deletions amenable to exon 45 or exon 53 skipping. Twice as many patients will receive active treatment as will receive placebo (2:1 randomization).
Eligibility criteria include but are not limited to:
Additional criteria apply and will be reviewed with patients during the screening process. The Principal Investigator (study doctor) determines whether a patient meets the inclusion criteria for the study, and therefore whether or not the patient is eligible to participate.
60 global sites are planned to participate in ESSENCE. Please see clinicaltrials.gov for updates (Identifier NCT02500381).
No, some patients will receive active treatment and some patients will receive placebo (2:1 randomization).
Comparing patients receiving active drug against patients receiving placebo helps to understand how a drug affects patients and to determine whether the investigational agent is effective and safe.
While no benefit can be guaranteed from participation in any clinical study, enrolled participants may:
Choosing to participate in a clinical study is an important and personal decision. It is recommended that you speak with your doctor, family members, and/or friends about participating in this study.
Generally, travel costs associated with participation in the study will be paid up-front, and incidental costs (parking, meals, etc.) are reimbursed. We do not offer a stipend for participation in the ESSENCE trial. Additional information regarding reimbursement and compensation can be provided by a participating study site.
The Principal Investigator (study doctor) and/or the study site contact will review study requirements with all patients during the screening process.
All patients will receive weekly infusions over 96 weeks. Patients in the treated group will receive an infusion of investigational therapy, and patients in the untreated group will receive a placebo infusion. Neither the doctor nor the patient will know whether or not the infusion is placebo or investigational therapy during the 96 weeks. After 96 weeks, an open-label extension will continue for up to 96 weeks. During the open-label extension, all patients will receive investigational agent, and no patients will receive placebo.
Clinical efficacy will be assessed at regularly scheduled study visits, including functional tests such as the six minute walk test. All patients will undergo a muscle biopsy at baseline and a second muscle biopsy at either Week 48 or Week 96.
Safety will be assessed through the collection of side effect information, laboratory tests, electrocardiograms (ECGs), echocardiograms (ECHOs), vital signs, and physical examinations throughout the study.
Blood samples will be taken periodically throughout the study to assess levels of drug in the bloodstream (pharmacokinetics) and to monitor patient safety.
ESSENCE has reached targeted enrollment in the US and is no longer enrolling patients in the US. Enrollment is continuing in other countries. To learn more information about the ESSENCE study, please visit www.clinicaltrials.gov (Identifier NCT02500381) or essencetrial.com. You may also email email@example.com or call +1-888-727-3782.